Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Small RNAs deliver a blow to ovarian cancer.

Kasinski A, Slack FJ.

Cancer Discov. 2013 Nov;3(11):1220-1. doi: 10.1158/2159-8290.CD-13-0667.

2.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA.

Cancer Discov. 2013 Nov;3(11):1302-15. doi: 10.1158/2159-8290.CD-13-0159. Epub 2013 Sep 3.

3.

EphA2 as a target for ovarian cancer therapy.

Landen CN, Kinch MS, Sood AK.

Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. Review.

PMID:
16300469
4.

siRNA and miRNA for the treatment of cancer.

Jankovic R, Radulovic S, Brankovic-Magic M.

J BUON. 2009 Sep;14 Suppl 1:S43-9. Review.

PMID:
19785069
5.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
6.

Liposomal siRNA for ovarian cancer.

Mangala LS, Han HD, Lopez-Berestein G, Sood AK.

Methods Mol Biol. 2009;555:29-42. doi: 10.1007/978-1-60327-295-7_3.

PMID:
19495686
7.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK.

Cancer Res. 2005 Aug 1;65(15):6910-8.

9.

[Advances in research on RNA interference-related drugs for cancer treatment].

Ren HW, Yang BX.

Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):801-4. doi: 10.3760/cma.j.issn.0253-3766.2012.11.001. Review. Chinese. No abstract available.

PMID:
23291125
10.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
11.

Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.

Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J.

Neoplasma. 2012;59(1):105-13.

PMID:
22103904
12.

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.

Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27.

13.

Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.

Rettew AN, Getty PJ, Greenfield EM.

Adv Exp Med Biol. 2014;804:47-66. doi: 10.1007/978-3-319-04843-7_3. Review.

PMID:
24924168
14.

Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening.

Toledo-Sherman L, Deretey E, Slon-Usakiewicz JJ, Ng W, Dai JR, Foster JE, Redden PR, Uger MD, Liao LC, Pasternak A, Reid N.

J Med Chem. 2005 May 5;48(9):3221-30.

PMID:
15857128
15.

miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.

Samuel P, Pink RC, Brooks SA, Carter DR.

Expert Rev Anticancer Ther. 2016;16(1):57-70. doi: 10.1586/14737140.2016.1121107. Epub 2015 Dec 5. Review.

PMID:
26567444
16.

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.

Zhang T, Guan M, Jin HY, Lu Y.

Gynecol Oncol. 2005 May;97(2):501-7.

PMID:
15863151
17.
18.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. Epub 2010 Dec 15.

19.

Biomarkers for ovarian cancer detection and therapy.

Dutta S, Wang FQ, Phalen A, Fishman DA.

Cancer Biol Ther. 2010 May 1;9(9):668-77. Epub 2010 May 24. Review.

PMID:
20372062
20.

Dual targeting of EphA2 and FAK in ovarian carcinoma.

Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK.

Cancer Biol Ther. 2009 Jun;8(11):1027-34. Epub 2009 Jun 24.

Supplemental Content

Support Center